Firefly Neuroscience, Inc. ("Firefly" or the "Company") (NASDAQ: AIFF), an artificial intelligence ("AI") company advancing precision neuroscience and non-invasive brain-computer interface (BCI) technology, today provided an update on its non-invasive brain-computer interface ("BCI") strategy, highlighting the role of its commercially available Versus platform in pursuing the human-performance market.

Building on the Versus commercial launch, Firefly is outlining how the platform fits within its broader strategy to translate brain signals into practical applications across brain health and human performance. Versus combines a wireless EEG headset with interactive training software, enabling users to control simulation and other apps through real-time brainwave activity.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.